Abstract 6770: Acquired temozolomide resistance instructs patterns of glioblastoma cell motility and proteome expression within gelatin hydrogels

Abstract Acquired drug resistance in glioblastoma (GBM) presents a major clinical challenge and is one of the key factors contributing to the abysmal prognosis with less than 15 months median overall survival. The aggressive chemotherapy with the frontline therapeutic, temozolomide (TMZ), ultimately fails to kill residual, highly invasive tumor cells after surgical resection and radiotherapy. Here, we present a robust three-dimensional (3D) in vitro hydrogel model of acquired temozolomide (TMZ) resistance using isogenically-matched glioblastoma (GBM) cell lines. We demonstrate distinct drug response patterns between TMZ-sensitive and TMZ-resistant GBM cells, emphasizing our model's promise for future pre-clinical investigations aimed at developing novel therapies targeting drug-resistant GBM. Importantly, our model detects apoptosis-related protein changes in response to TMZ, validating its ability to study drug-induced molecular changes. Furthermore, our study delves into the migratory potential of GBM cells within the 3D extracellular matrix environment. Additionally, we uncover significant alterations in cytokine expression associated with matrix remodeling and angiogenesis, providing new avenues for therapeutic investigation. Although our findings are derived from a specific set of isogenically-matched cell lines, this model highlights the potential to explore personalized treatment strategies. Ongoing research in our lab is dedicated to gaining a more profound understanding of matrix remodeling and the migratory potential of TMZ-resistant GBM cells. Moreover, our future work will aim to expand our study to include a wider range of cell lines and patient-derived xenografts within our advanced microphysiological systems that include key elements of GBM tumor microenvironment such as perivascular niche. This endeavor seeks to establish connections between observed therapeutic behaviors and clinical outcomes, ultimately contributing to the development of more effective treatments for GBM patients. Citation Format: Viktoriia Kriuchkovskaia, Ela Eames, Rebecca Riggins, Brendan Harley. Acquired temozolomide resistance instructs patterns of glioblastoma cell motility and proteome expression within gelatin hydrogels abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts) ; 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84 (6Suppl): Abstract nr 6770.